内地第二大疫苗制造企业艾美疫苗股份已提交主板上市申请，联席保荐人为高盛、中金、中信建投国际、麦格理。据初步招股文件显示，艾美疫苗是国内最大的全产业链民营疫苗集团，在去年取得了约6,000万剂的批签发量，同时也是内地仅次於中国生物的第二大疫苗制造企业。公司目前已商业化8款针对6个疾病领域的疫苗产品，包括狂犬病、乙型肝炎、甲型肝炎、腮腺炎、肾综合征出血热及脑膜炎球菌病，亦有针对13个疾病领域的23种在研疫苗。另外，公司亦是国内唯一采用经获批准新冠疫苗产品验证的所有四种技术路线，即mRNA、灭活病毒、重组腺病毒载体及重组蛋白的COVID-19疫苗开发商。於2018年、2019年及2020年，总收益分别为人民币11.1亿元人民币(下同)、9.5亿元及16.38亿元。纯利从2018年的1.01亿元增至2019年的1.2亿元，并进一步增至2020年的4亿元，复合年增长率为98.7%，成为中国增长最快的国内疫苗市场参与者之一。(ha/a)~阿思达克财经新闻网址: www.aastocks.com
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Comments